TITLE:

Approach to management of chronic cough and chronic airway diseases: "Treatable traits" or correct diagnosis?

AUTHOR(S):

Matsumoto, Hisako

CITATION:

Matsumoto, Hisako. Approach to management of chronic cough and chronic airway diseases: "Treatable traits" or correct diagnosis?. Respiratory Investigation 2020, 58(3): 129-130

ISSUE DATE:

2020-05

URL:

<http://hdl.handle.net/2433/251017>

RIGHT:

© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>; The full-text file will be made open to the public on 1 May 2021 in accordance with publisher's 'Terms and Conditions for Self-Archiving'; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。 ; This is not the published version. Please cite only the published version.

Editorial

Treatable traits or correct diagnosis? Thoughts on chronic cough and chronic airway diseases

Department of Respiratory Medicine, Kyoto University, Kyoto, Japan

Hisako Matsumoto

54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Japan

Tel: +81-75-751-3830

Fax: +81-75-751-4643

E-mail: hmatsumo@kuhp.kyoto-u.ac.jp

Treatable traits are a recently introduced and important concept in the management of chronic airway diseases such as chronic obstructive pulmonary disease (COPD) and asthma [1]. Recently, this concept of treatable traits has been introduced in the management of chronic cough. The management of chronic persistent cough has improved significantly by following an anatomical diagnostic protocol. The diagnosis of underlying diseases such as cough-variant asthma and gastroesophageal reflux has advanced the understanding of pathology and the management of chronic cough. Conversely, cough hypersensitivity that may reflect a complex interplay between peripheral (cough sensory nerves) and central (brain stem and higher centers) nervous system has been proposed more than 15 years ago and has now found acceptance, particularly in Europe, as an important concept encompassing cough with various etiologies [2]. The most recent guidelines on the diagnosis and treatment of chronic cough published by the European Respiratory Society emphasize the potential role of cough hypersensitivity in adult patients with chronic cough [3] who respond to an exposure to low levels of thermal, chemical, or mechanical stimulation [4]. In these guidelines, the diagnostic labels for chronic cough are replaced with treatable traits or phenotypes of chronic cough, described as asthmatic cough, reflux cough, and upper airways cough syndrome. The Japanese Respiratory Society guidelines for the management of cough and sputum have also introduced cough hypersensitivity syndrome as an emerging concept [5]. Although there remains some room for debate, cough hypersensitivity can be included in the management of chronic cough based on promising results with potential new treatments including purinergic P2X3 receptor antagonists [6]. In addition, every effort should be made to identify the underlying conditions that augment the sensitivity of peripheral nervous system, whichever terms of treatable traits or diagnosis

are used.

In contrast to chronic cough, the re-emphasis appears to be on “correct diagnosis” in COPD and asthma. One of the major treatable traits in obstructive airway diseases is elevated blood eosinophil counts. In both asthma and COPD, the risk of exacerbation increases by about 1.2–1.3 in patients with blood eosinophil counts above 300 cells/ μ L [7] [8]. Blood eosinophilia is a useful parameter for managing patients with COPD because the addition of inhaled corticosteroids may decrease the exacerbation frequency in this population, even though it may also increase the risks of pneumonia [9]. In contrast, blood eosinophil counts have been reported not to be very informative regarding the induction of anti-interleukin-5 class biologics in patients with COPD [10] [11] when compared with its efficacy in eosinophilic asthma. This difference might be due to the relatively smaller percentage of patients with severe eosinophilia within the overall COPD population compared to those with asthma; however, a recent study may provide a clue to the discrepant roles of blood eosinophil count between eosinophilic COPD and eosinophilic asthma [12]. In this study, despite having similar elevated blood eosinophil counts (>200 cells/ μ L) and elevated serum total IgE levels, only *CST1* gene, a gene encoding cystatin-SN that belongs to type 2 cystatin family, was correlated with blood eosinophil counts in both eosinophilic COPD and eosinophilic asthma. This finding suggests that eosinophilic COPD and eosinophilic asthma share the treatable trait of blood eosinophilia, but molecular mechanisms underlying this trait in two diseases are substantially different. In conclusion, the recognition of treatable traits is clearly important in clinical practice; however, correct diagnosis and efforts to identify the underlying mechanisms should be a continuous priority.

References

- [1] Matsumoto H. Our obligation to find treatable and untreatable traits in patients with chronic airway diseases. *Respir Investig*. 2019; 57: 293-4.
- [2] Chung KF, McGarvey L, Mazzone SB. Chronic cough as a neuropathic disorder. *Lancet Respir Med*. 2013; 1: 414-22.
- [3] Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Ribas CD, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. *Eur Respir J*. 2019: E-pub ahead of print.
- [4] Matsumoto H, Izuhara Y, Niimi A, Tabara Y, Nagasaki T, Kanemitsu Y, et al. Risks and Cough-Aggravating Factors in Prolonged Cough. *Epidemiological Observations from the Nagahama Cohort Study*. *Ann Am Thorac Soc*. 2017; 14: 698-705.
- [5] The JRS guidelines for the management of cough and sputum (in Japanese). 2019.

- [6] Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. *Lancet*. 2015; 385: 1198-205.
- [7] Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. *Lancet Respir Med*. 2015; 3: 849-58.
- [8] Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol*. 2018; 141: 2037-47 e10.
- [9] Cheng SL. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis. *Int J Chron Obstruct Pulmon Dis*. 2018; 13: 2775-84.
- [10] Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. *N Engl J Med*. 2017; 377: 1613-29.
- [11] Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, et al. Benralizumab for the Prevention of COPD Exacerbations. *N Engl J Med*. 2019; 381: 1023-34.
- [12] George L, Taylor AR, Esteve-Codina A, Soler Artigas M, Thun GA, Bates S, et al. Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. *Allergy*. 2019.